Search results
Results from the WOW.Com Content Network
The WHO has developed a multinational coalition of vaccine scientists defining a Global Target Product Profile (TPP) for COVID-19, identifying favorable attributes of safe and effective vaccines under two broad categories: "vaccines for the long-term protection of people at higher risk of COVID-19, such as healthcare workers", and other ...
Koçak-19 Inaktif Adjuvanlı COVID-19 vaccine Kocak Farma Turkey Inactivated SARS‑CoV‑2: Phase I (38) [231] Phase 1 Study for the Determination of Safety and Immunogenicity of Different Strengths of Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.
The UNESCO study of publication trends in 193 countries on the topic of new or re-emerging viruses that can infect humans covered the period from 2011 to 2019 and now provides an overview of the state of research prior to the COVID-19 pandemic. Global output on this broad topic increased by only 2% per year between 2011 and 2019, slower than ...
The Canadian government announced CA$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian universities, [179] [180] with plans to establish a "vaccine bank" of new vaccines for implementation if another COVID-19 outbreak occurs.
COVI-VAC (codenamed CDX-005) is a COVID-19 vaccine developed by Codagenix, Inc. In December 2020, COVI-VAC started a Phase I clinical trial , involving 48 participants. The trial was scheduled to complete in June 2021, with results to be reported by May 2022.
As of late 2020, several mRNA vaccines for SARS-CoV-2 use LNPs as their drug delivery system, including both the Moderna COVID-19 vaccine and the Pfizer–BioNTech COVID-19 vaccines. [4] Moderna uses its own proprietary ionizable cationic lipid called SM-102, while Pfizer and BioNTech licensed an ionizable cationic lipid called ALC-0315 from ...
In April, Ad5-nCoV became the first COVID-19 vaccine candidate in the world to begin Phase II trials. [30] The Phase II trial results were published in the peer-reviewed journal The Lancet in August 2020, and noted neutralizing antibody and T cell responses based on statistical analyses of data involving 508 eligible participants. [ 31 ]
The vaccine has been developed by collaborating scientists at VABIOTECH in Hanoi and the Bristol University, it will be tested further in animals and evaluated for safety and effectiveness before a manufacturing process is embarked on. According to the National Institute of Hygiene and Epidemiology, it will take at least 12–18 months to ...